483 related articles for article (PubMed ID: 12124824)
1. Clinicopathologic study of 123 cases of prolactin-secreting pituitary adenomas with special reference to multihormone production and clonality of the adenomas.
Ma W; Ikeda H; Yoshimoto T
Cancer; 2002 Jul; 95(2):258-66. PubMed ID: 12124824
[TBL] [Abstract][Full Text] [Related]
2. [Clinicopathology, clonality, and hormone production profile of prolactinoma].
Ma WB; Ikeda H; Yoshimoto T
Zhonghua Yi Xue Za Zhi; 2005 Jun; 85(20):1382-7. PubMed ID: 16029648
[TBL] [Abstract][Full Text] [Related]
3. Comparative immunohistochemical analysis of estrogen receptor and chromogranin-A reactivity in plurihormonal human prolactinomas.
Talan-Hranilović J; Gnjidić Z; Sajko T; Vizner B; Vrkljan M
Acta Med Croatica; 2000; 54(2):59-63. PubMed ID: 11028110
[TBL] [Abstract][Full Text] [Related]
4. Gender-related differences in prolactin secretion in pituitary prolactinomas.
Nishioka H; Haraoka J; Akada K; Azuma S
Neuroradiology; 2002 May; 44(5):407-10. PubMed ID: 12012125
[TBL] [Abstract][Full Text] [Related]
5. Pituitary tumors and hyperplasia in multiple endocrine neoplasia type 1 syndrome (MEN1): a case-control study in a series of 77 patients versus 2509 non-MEN1 patients.
Trouillas J; Labat-Moleur F; Sturm N; Kujas M; Heymann MF; Figarella-Branger D; Patey M; Mazucca M; Decullier E; Vergès B; Chabre O; Calender A;
Am J Surg Pathol; 2008 Apr; 32(4):534-43. PubMed ID: 18300794
[TBL] [Abstract][Full Text] [Related]
6. Do the limits of serum prolactin in disconnection hyperprolactinaemia need re-definition? A study of 226 patients with histologically verified non-functioning pituitary macroadenoma.
Karavitaki N; Thanabalasingham G; Shore HC; Trifanescu R; Ansorge O; Meston N; Turner HE; Wass JA
Clin Endocrinol (Oxf); 2006 Oct; 65(4):524-9. PubMed ID: 16984247
[TBL] [Abstract][Full Text] [Related]
7. [Immunohistochemistry for pituitary hormones and Ki-67 in growth hormone producing pituitary adenomas].
Brito J; Sáez L; Lemp M; Liberman C; Michelsen H; Araya AV
Rev Med Chil; 2008 Jul; 136(7):831-6. PubMed ID: 18949157
[TBL] [Abstract][Full Text] [Related]
8. Clinical and histological correlations in prolactinomas, with special reference to bromocriptine resistance.
Delgrange E; Sassolas G; Perrin G; Jan M; Trouillas J
Acta Neurochir (Wien); 2005 Jul; 147(7):751-7; discussion 757-8. PubMed ID: 15971099
[TBL] [Abstract][Full Text] [Related]
9. Tissue kallikrein and the effect of bromocriptine in human prolactin and growth hormone-secreting pituitary adenomas.
Jones TH; Figueroa CD; Smith CM; Bhoola KD
Agents Actions Suppl; 1992; 38 ( Pt 2)():175-82. PubMed ID: 1462825
[TBL] [Abstract][Full Text] [Related]
10. Immunohistochemical analysis of RCAS1 in human pituitary adenomas.
Umeoka K; Sanno N; Oyama K; Tahara S; Kurotani R; Ikuyama S; Nakashima M; Watanabe T; Osamura RY; Teramoto A
Mod Pathol; 2001 Dec; 14(12):1232-6. PubMed ID: 11743045
[TBL] [Abstract][Full Text] [Related]
11. Endocrinological outcome following first time transsphenoidal surgery for GH-, ACTH-, and PRL-secreting pituitary adenomas.
Kristof RA; Schramm J; Redel L; Neuloh G; Wichers M; Klingmüller D
Acta Neurochir (Wien); 2002 Jun; 144(6):555-61; discussion 561. PubMed ID: 12111488
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of hormone secretion in GH-secreting pituitary adenomas by receptor-subtype specific somatostatin analogues in vitro.
Cap J; Marekova M; Cerman J; Malirova E; Suba P; Netuka D; Hana V; Marek J
Gen Physiol Biophys; 2003 Jun; 22(2):201-12. PubMed ID: 14661732
[TBL] [Abstract][Full Text] [Related]
13. Effect of vasoactive intestinal polypeptide (VIP) on growth hormone (GH) and prolactin (PRL) release and cell morphology in human pituitary adenoma cell cultures.
Fazekas I; Bácsy E; Varga I; Slowik F; Bálint K; Pásztor E; Czirják S; Gláz E
Folia Histochem Cytobiol; 2000; 38(3):119-27. PubMed ID: 10970071
[TBL] [Abstract][Full Text] [Related]
14. Pituitary adenomas: immunohistochemical: study of 90 cases.
Kasantikul V; Shuangshoti S
J Med Assoc Thai; 1990 Sep; 73(9):514-21. PubMed ID: 2262756
[TBL] [Abstract][Full Text] [Related]
15. Fractionated stereotactic conformal radiotherapy for secreting and nonsecreting pituitary adenomas.
Minniti G; Traish D; Ashley S; Gonsalves A; Brada M
Clin Endocrinol (Oxf); 2006 May; 64(5):542-8. PubMed ID: 16649974
[TBL] [Abstract][Full Text] [Related]
16. PTTG expression in different experimental and human prolactinomas in relation to dopaminergic control of lactotropes.
Cristina C; Díaz-Torga GS; Goya RG; Kakar SS; Perez-Millán MI; Passos VQ; Giannella-Neto D; Bronstein MD; Becu-Villalobos D
Mol Cancer; 2007 Jan; 6():4. PubMed ID: 17222350
[TBL] [Abstract][Full Text] [Related]
17. Plurihormonal pituitary adenomas.
Scheithauer BW; Horvath E; Kovacs K; Laws ER; Randall RV; Ryan N
Semin Diagn Pathol; 1986 Feb; 3(1):69-82. PubMed ID: 3039632
[TBL] [Abstract][Full Text] [Related]
18. Prolactinomas express human heparin-binding secretory transforming gene (hst) protein product: marker of tumour invasiveness.
Shimon I; Hinton DR; Weiss MH; Melmed S
Clin Endocrinol (Oxf); 1998 Jan; 48(1):23-9. PubMed ID: 9509064
[TBL] [Abstract][Full Text] [Related]
19. Human growth hormone and prolactin secreting pituitary adenomas analyzed by in situ hybridization.
Lloyd RV; Cano M; Chandler WF; Barkan AL; Horvath E; Kovacs K
Am J Pathol; 1989 Mar; 134(3):605-13. PubMed ID: 2466405
[TBL] [Abstract][Full Text] [Related]
20. Spontaneous prolactin transplantable tumor in the Wistar/Furth rat (SMtTW): a new animal model of human prolactinoma.
Trouillas J; Girod C; Claustrat B; Joly-Pharaboz MO; Chevallier P
Cancer Res; 1990 Jul; 50(13):4081-6. PubMed ID: 2354457
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
